Hormone Refractory Prostate Cancer Market Report 2025

The hormone-refractory prostate cancer market size has grown rapidly in recent years. It will grow from $7.35 billion in 2024 to $8.12 billion in 2025 at a compound annual growth rate (CAGR) of 10.4%. The growth during the historic period can be attributed to the rising incidence of prostate cancer, increased prostate-specific antigen (PSA) screening, greater physician awareness and specialization, expanded use of palliative care, and a growing number of clinical trials.

The hormone-refractory prostate cancer market size is expected to see rapid growth in the next few years. It will grow to $11.91 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The projected growth in the forecast period can be attributed to the increased use of genetic biomarkers, rising adoption of precision medicine, expansion of PARP inhibitors, broader global access to HRPC treatments, and growing clinical use of combination therapy regimens. Key trends expected during this time include wider adoption of combination therapies, advancements in radiopharmaceuticals, integration of next-generation sequencing (NGS), digital tools, and remote monitoring, as well as the development of next-generation androgen receptor inhibitors and PARP inhibitors for HRPC.

Increasing investment in cancer research worldwide is expected to drive the growth of the hormone-refractory prostate cancer market going forward. Investment in cancer research includes funding and resources aimed at advancing innovative methods for cancer detection, treatment, and prevention. This investment is rising due to the growing global cancer burden, which creates a demand for more effective and targeted therapies. Funding supports innovation in hormone-refractory prostate cancer treatments by enabling advanced therapies like radioligand treatments and hormone inhibitors. It also backs clinical trials and biomarker studies to improve treatment precision and outcomes. For example, in August 2024, the Cancer Research Institute (CRI), a US-based nonprofit focused on immunotherapy research, invested approximately $22.8 million in the 2023-2024 fiscal year, providing 64 new grants to researchers at 42 institutions across seven countries. Therefore, the increasing investment in cancer research is propelling the hormone-refractory prostate cancer market growth.

Key companies in the hormone-refractory prostate cancer market are concentrating on developing advanced treatments such as intravenous radioligand therapy to improve survival rates among patients with resistant prostate cancer. Intravenous radioligand therapy is a targeted treatment that uses radioactive molecules linked to ligands to identify and bind cancer-specific markers, destroying cancer cells internally while sparing healthy surrounding tissue. For instance, in March 2025, Novartis AG, a Switzerland-based pharmaceutical company, launched Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which received FDA approval. This therapy is intended for earlier treatment of patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with an androgen receptor pathway inhibitor (ARPI) and are candidates to delay chemotherapy. Based on the Phase III PSMAfore trial, this expanded indication roughly triples the eligible patient population and demonstrated that Pluvicto reduced the risk of radiographic progression or death by 59%, while more than doubling median radiographic progression-free survival compared to a change in ARPI. Pluvicto is the first targeted radioligand therapy approved for use before chemotherapy in this context, providing a new treatment option that delays disease progression with a favorable safety profile.

In June 2024, AstraZeneca, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.4 billion. This acquisition aims to strengthen AstraZeneca’s oncology portfolio by adding next-generation radioconjugate therapies, including FPI-2265 for metastatic castration-resistant prostate cancer (mCRPC), and to enhance its radiopharmaceutical research, development, manufacturing, and supply capabilities. Fusion Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company specializing in treatments for metastatic castration-resistant prostate cancer.

Major players in the hormone refractory prostate cancer market are Pfizer Inc., Johnson And Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Novartis AG, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Ipsen Pharma, Exelixis Inc., Orion Corporation, Lantheus Holdings Inc., Clovis Oncology Inc., Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC.

North America was the largest region in the hormone-refractory prostate cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hormone-refractory prostate cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hormone-refractory prostate cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hormone-refractory prostate cancer (HRPC) market consists of revenues earned by entities by providing services such as oncology consultations, advanced imaging, molecular diagnostic testing, clinical trial participation, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hormone-refractory prostate cancer (HRPC) market also includes sales of next-generation androgen receptor inhibitors, radiopharmaceuticals, and bone health agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The hormone refractory prostate cancer market research report is one of a series of new reports that provides hormone refractory prostate cancer market statistics, including the hormone refractory prostate cancer industry global market size, regional shares, competitors with the hormone refractory prostate cancer market share, detailed hormone refractory prostate cancer market segments, market trends, opportunities, and any further data you may need to thrive in the hormone refractory prostate cancer industry. This hormone refractory prostate cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Hormone-refractory prostate cancer (HRPC), also called castration-resistant prostate cancer (CRPC), is a type of prostate cancer that progresses even after testosterone levels have been lowered through androgen deprivation therapy (ADT). This progression may be detected by rising prostate-specific antigen (PSA) levels, imaging evidence of new or enlarging tumors, or worsening clinical symptoms. HRPC is an advanced and treatment-resistant form of prostate cancer that often requires systemic therapies beyond standard hormone suppression.

The primary treatment options for hormone-refractory prostate cancer include chemotherapy, hormonal therapy, immunotherapy, radiation therapy, and surgery. Chemotherapy involves the use of potent drugs to target cancer cells that no longer respond to hormone therapy and have metastasized. These treatments are supplied through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by a range of end users including hospitals, ambulatory surgical centers, specialty clinics, and others.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.